REBECCA SCHULTZ: Open Payments
NPI 1760957351 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$711 in 42 payments from 12 companies in 2025. Trend: 2023 $909 · 2024 $905 · 2025 $711
Food & beverage: $711
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $191 |
| Lilly USA, LLC | 13 | $186 |
| ABBVIE INC. | 3 | $65 |
| GlaxoSmithKline, LLC. | 4 | $65 |
| Lundbeck LLC | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| PFIZER INC. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Novo Nordisk Inc | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
Products named: MOUNJARO, FARXIGA, REXULTI, TRELEGY ELLIPTA, JARDIANCE, BREZTRI, AIRSUPRA, VRAYLAR.
Industry payments across AR — which companies pay providers there.
